Michael Ehlers, Ascidian Therapeutics CEO (Photo: Kevin Trimmer)

Roche strikes neu­ro-fo­cused part­ner­ship with RNA ex­on edit­ing start­up, worth as much as $1.8B

Roche has tapped a small Boston start­up for ac­cess to a sweep­ing form of RNA edit­ing that re­places large swathes of er­rant ge­net­ic code. Broad­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.